SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/20 EXACT Sciences Corporation 8-K:1,8,9 2/24/20 15:1.2M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 49K 2: EX-1.1 Underwriting Agreement HTML 255K 3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 349K 4: EX-5.1 Opinion of Counsel re: Legality HTML 21K 5: EX-99.1 Miscellaneous Exhibit HTML 14K 6: EX-99.2 Miscellaneous Exhibit HTML 16K 11: R1 Cover HTML 48K 14: XML IDEA XML File -- Filing Summary XML 13K 13: XML XBRL Instance -- tm2011194-1_8k_htm XML 15K 12: EXCEL IDEA Workbook of Financial Reports XLSX 6K 8: EX-101.LAB XBRL Labels -- exas-20200224_lab XML 97K 9: EX-101.PRE XBRL Presentations -- exas-20200224_pre XML 65K 7: EX-101.SCH XBRL Schema -- exas-20200224 XSD 13K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 15: ZIP XBRL Zipped Folder -- 0001104659-20-026285-xbrl Zip 131K
Exhibit 99.1
Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028
MADISON, Wis., Feb. 24, 2020 -- Exact Sciences Corporation (NASDAQ: EXAS) (the “Company”) today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the “Notes”) pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $127.5 million aggregate principal amount of the Notes. The Company intends to use the net proceeds of this offering for general corporate purposes, which may include the repayment or repurchase of debt, working capital and possible acquisitions. The Notes will be convertible into cash, shares of the Company’s common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company’s election.
BofA Securities is acting as sole book-running manager for the Notes offering.
An automatically effective shelf registration statement relating to the Notes was filed with the SEC on June 6, 2017. The offering of the Notes will be made only by means of the prospectus and related prospectus supplement, which have been or will be filed with the SEC. A copy of the prospectus supplement and prospectus relating to the Notes offering may be obtained free of charge on the SEC’s website at http://www.sec.gov or by sending a request to BofA Securities, NC1-004-03-43 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department (or by e-mail at dg.prospectus_requests@bofa.com).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
C:
Forward-Looking Statements
Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: the terms and size of the offering and the use of proceeds from the offering. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the Company’s most recently filed Annual Report on Form 10-K. The Company urges you to consider those risks and uncertainties in evaluating the Company’s forward-looking statements. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Contact:
Megan Jones
Exact Sciences Corp.
608-535-8815
Source: Exact Sciences Corporation
C:
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/27/20 | 4 | ||
For Period end: | 2/24/20 | 4, 424B5 | ||
6/6/17 | 424B5, 8-K, S-3ASR | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/21/24 Exact Sciences Corp. 10-K 12/31/23 128:15M 3/17/23 Exact Sciences Corp. 424B7 2:659K 2/21/23 Exact Sciences Corp. 10-K 12/31/22 128:17M 5/02/22 Exact Sciences Corp. 424B7 2:638K 2/22/22 Exact Sciences Corp. 10-K 12/31/21 143:18M 1/10/22 Exact Sciences Corp. 424B7 1:624K 6/07/21 Exact Sciences Corp. 424B7 1:610K 2/16/21 Exact Sciences Corp. 10-K 12/31/20 139:16M 1/05/21 Exact Sciences Corp. 424B7 1:669K 1/05/21 Exact Sciences Corp. S-8 1/05/21 5:264K 10/27/20 Exact Sciences Corp. 424B2 1:624K Toppan Merrill/FA |